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Modesti, Pietro Amedeo, Ilaria Cecioni, Angela Mi-
gliorini, Alessandra Naldoni, Alessandro Costoli, Si-
mone Vanni, and Gian Gastone Neri Serneri. Increased
renal endothelin formation is associated with sodium reten-
tion and increased free water clearance. Am. J. Physiol. 275
(Heart Circ. Physiol. 44): H1070–H1077, 1998.—To investi-
gate whether renal endothelin (ET)-1 participates in water
and sodium handling, we investigated the influence of differ-
ent sodium intakes on renal production of ET-1 in eight
healthy subjects. The functional relationship with the renin-
angiotensin system was also studied. Renal ET-1 formation is
affected by sodium intake, because 1 wk of high sodium
decreased urinary ET-1 excretion (234%, P , 0.05), whereas
a low-sodium diet increased ET-1 excretion (66%, P , 0.05)
and mRNA expression for preproendothelin-1 in epithelial
cells of medullary collecting ducts and endothelial cells of the
peritubular capillary network. Increased ET-1 renal synthe-
sis was associated with sodium retention and increased free
water clearance. Urinary ET-1 excretion changes from nor-
mal to low-sodium diet were negatively related to contempo-
rary changes in sodium excretion (r 5 0.97, P , 0.05) and
were positively correlated with free water clearance (r 5 0.97,
P , 0.05). These correlations were maintained during angio-
tensin-converting enzyme inhibition, which only partially
reduced ET-1 renal excretion. These results indicate that
renal ET-1 production is indeed modulated by varying sodium
intakes and may exert a role in sodium and water handling.
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ABUNDANT EXPRESSION of endothelin (ET)-1 peptide and
mRNAfor its precursor, preproendothelin-1 (prepro-ET-
1), have been found in the vascular endothelium of the
renal vascular bed, including glomerular capillaries,
arterioles, and peritubular capillaries (15, 24). Subse-
quent studies have demonstrated that ET-1 is present
in high concentrations in the inner medulla of the
kidney (24), where ET-1 receptors are also located (5),
and that ET-1 secretion is not limited to vascular
endothelium, because primary epithelial cell cultures
derived from the renal tubule secrete abundant amounts
of ET-1 (10). ET-1 secretion in the renal medulla is
highly compartmentalized in tubules with the follow-
ing secretion hierarchy: inner medullary collecting
ducts (IMCD) . medullary thick ascending limb .
cortical collecting ducts . proximal tubule (11, 29).
The physiological activities of ET-1 on renal sodium
and water handling still remain to be clarified (11).
Convincing evidence exists that ET-1 may inhibit argi-
nine vasopressin (AVP)-stimulated water reabsorption
in the collecting ducts. Several studies have demon-
strated that ET-1 binding to the ETB receptor subtype
reduces Na1-K1-ATPase activity in the IMCD (34) and
inhibits vasopressin-stimulated cAMP accumulation
and water transport on isolated cortical collecting ducts
from rats (23, 30). These and other studies (11, 29)
indicate that ET-1 might regulate water reabsorption
independently of its effects on Na1 reabsorption or
renal hemodynamics.
Studies investigating the activity of ET-1 on sodium
reabsorption have given conflicting or unconvincing
results. ET-1 inhibited Na1-K1-ATPase activity in a
suspension of rabbit IMCD (34), suggesting a possible
natriuretic effect. Administration of anti-ET-1 antibod-
ies to rats on a low-sodium diet increased urinary salt
and water (32). Experiments performed by infusing
ET-1 in isolated rat kidney (22) or in vivo gave conflict-
ing results, because either a sodium-retentive (8) or a
natriuretic (13, 31) effect was observed. However, the
natriuresis observed after ET-1 infusion might result
from release of the atrial natriuretic peptide (ANP)
induced by ET-1 infusion (19). Moreover, the natri-
uretic effect might be secondary to hemodynamic
changes such as the increase in arterial blood pressure
(pressure natriuresis) (31). On the other hand, the
sodium retention reported after ET-1 infusion both in
rabbits (8) and in humans (25) might be caused by
intrarenal blood flow redistribution even if the total
renal blood flow was not decreased (25).
Thus the pharmacological approach to investigation
of physiological function as performed by infusing ET-1
may be confounding because the active agents can
provoke additional known or unknown effects. Studies
performed in humans without ET-1 infusion but repro-
ducing some physiological situations have shown that
urinary ET-1 is inversely related to changes in blood
volume. Acute volume expansion caused, in addition to
the notable increase in urinary volume, a marked
decrease in urinary ET-1 excretion (21). Conversely, a
sustained enhancement of urinary ET-1 excretion with
a considerable decrease in urinary volume and sodium
excretion occurred during long-lasting standing pos-
ture (17). These findings suggest that renal ET-1 may
be involved in the mechanisms of control of diuresis and
natriuresis.
To investigate this hypothesis we studied whether
different sodium intakes affect synthesis of renal ET-1.
Because experimental studies (27) and investigations
performed in humans (17) suggest that angiotensin-
converting enzyme (ACE) inhibition may influence
renal ET-1 excretion, we studied renal ET-1 excretion
during a low-sodium diet in the presence of inhibition of
ANG II formation.
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METHODS
Subjects Investigated
Eight healthy subjects of ages 25–38 yr (5 males and 3
females), volunteers for the present investigation, were stud-
ied. Experimental procedures and the purposes of the study
were explained to the subjects, and all of them gave their
informed consent. No subject was a smoker or had taken any
drug for at least 4 wk. Before the investigation serum
electrolytes, fasting plasma glucose, creatinine clearance,
and urinalysis were tested in all subjects. No pathological
finding emerged, and creatinine clearance ranged within
commonly accepted normal values (range of subjects investi-
gated: 97–135 ml/min). All subjects had the same lifestyle
during the sample-collecting days: breakfast at about 8:30
AM, lunch at about 1:00 PM, and an evening meal at 8:00 PM.
They went to sleep at 11:00 PM and woke up at 7:00 AM.
Experimental Protocols
All subjects underwent three 7-day periods of different
sodium intake (low, 20 meq/day; normal, 108 meq/day; high,
300 meq/day) in a randomized order. After the 7 days of
low-sodium diet subjects maintained this regimen and were
treated with an ACE inhibitor (ramipril, 5 mg/day) for
another 7 days. The three diet periods were separated from
one another by 1 wk of a normal-sodium diet.
In another separate set of experiments, after one wash-out
week on a normal-sodium diet, the subjects were treated with
ramipril (5 mg/day) for 7 days and then underwent a 7-day
low-sodium diet period while they continued ramipril treat-
ment.
Throughout the experimental periods the subjects had the
same basic diet containing a constant amount of protein (1.3
g/kg), calories (126 kJ/kg), calcium (800 mg/24 h), and potas-
sium (80 meq/day). Urinary and plasma samples for the
determination of ET-1, sodium, lithium, osmolality, creati-
nine, and plasma renin activity (PRA) were taken daily
during the last 3 days before the different diet regimens
started and every day throughout the study periods.
Sampling Procedure and Radioimmunoassays
Blood and urine sample collection and ET-1 extraction were
performed as previously described (17, 21). Briefly, plasma
and urine samples were extracted with Sep-Pak C18 columns
(Waters, Milford, MA) that had been previously activated by
consecutive washing steps with methanol (for plasma) or
acetonitrile-trifluoracetic acid (TFA) (for urine). After wash-
ing, the adsorbed ET-1 was eluted with methanol (for plasma)
or acetonitrile-TFA (for urine). The ET-1 recovery rate, calcu-
lated by the addition of different concentrations of cold ET-1,
was 70 6 9% from plasma and 90 6 5% from urine. Samples
were then assayed by specific radioimmunoassay, using poly-
clonal rabbit anti-ET-1 serum (Peninsula, Belmont, CA), as
previously described (17, 21). Briefly, the extracted samples
were resuspended in phosphate buffer immediately before the
assay was performed. The standard ET-1 (Peninsula) or
plasma samples (100 µl) were mixed with 100 µl of rabbit
anti-ET-1 serum, diluted with radioimmunoassay buffer to a
final dilution of 1:72,000 (vol/vol) for plasma and 1:24,000
(vol/vol) for urine. Antibody cross-reactivities were 100% with
ET-1 (porcine, human), 7% with ET-2 (human), 7% with ET-3
(rat, human), 35% with Big ET (porcine), 17% with Big ET
(human), and 3% with sarafotoxin S6b. There was no cross-
reactivity with a-humanANP, brain natriuretic peptide (BNP;
porcine), ANG I, ANG II, ANG III, vasopressin, ACTH, or
vasoactive intestinal peptide (VIP). The minimum detectable
ET-1 concentration was 0.1 pg/ml. The coefficients of intra-
assay and interassay variations were 4 (n 5 11 samples) and
10 (n 5 11)%, respectively. Results were expressed as pico-
grams per milliliter (pg/ml) for plasma. Urinary ET-1 excre-
tion was expressed as picograms per milliliter and as amount
excreted per minute (pg/min).
Blood samples for PRA were collected in ice-cold tubes
containing EDTA (0.084 ml tripotassic EDTA in 7 ml blood;
final concentration 0.34 mol/l) and immediately centrifuged,
then stored at 220°C. PRA measurement was performed by
measuring the quantity of ANG I generated in vitro by
radioimmunoassay with a commercial kit (Sorin Biomedica)
and was expressed as nanograms of ANG I per milliliter of
plasma per hour of incubation.
Analytical Methods and Calculations
Plasma and urine were assayed for electrolytes (sodium
and lithium) with an ion-sensitive electrode (Instrumenta-
tion Beckmann Astra, Brea, CA) and for creatinine with the
Jaffe reaction (Instrumentation Beckmann Astra). Glomeru-
lar filtration rate (GFR) was estimated by the clearance of
endogenous creatinine. To better appreciate the effects of
ACE inhibition on urinary volume and sodium excretion
regardless of GFR variation, we also expressed urinary
volume and 24-h sodium excretions as the rate of excretion
per unit of creatinine clearance (CCr).
Free water clearance (CH2O) was calculated as
CH2O 5 (1 2 Uosm/Posm) 3 V
where Uosm (mosmol/kg H2O) and Posm (mosmol/kg H2O) are
the simultaneous urinary and plasma osmolalities, respec-
tively, and V (ml/min) is the simultaneous rate of urinary
volume flow. Negative values of CH2O occur when the urine is
hypertonic to the plasma.
Osmolar clearance, sodium clearance (CNa), lithium clear-
ance (CLi), and CCr were calculated using standard formulas.
CLi is a measure of fluid delivery from the proximal tubule to
the loop of Henle. The ratio of sodium to lithium clearances
(CNa/CLi) is thus a measure of that fraction of the sodium
delivered to the distal tubule which is finally excreted, and
CLi 2 CNa is a measure of the absolute rate of sodium
reabsorption from the distal tubule (3). Finally, we calculated
the cumulative sodium balance during the last 3 days of
sodium diet or ACE treatment period.
In Situ Hybridization
The expression of mRNA for prepro-ET-1 was investigated
in kidneys obtained in surgery from six patients affected with
localized renal tumors (age range 47–66 yr). Before surgery
patients underwent a 7-day period of normal (3 patients, 108
meq/day)- or low (3 patients, 20 meq/day)-sodium intake.
Kidney specimens were cut from the pole opposite the
tumor. Kidney portions containing cortex and medulla from
the six kidneys were fixed in 4% paraformaldehyde in 0.12 M
phosphate buffer (pH 7.2). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and prepro-ET-1 probes were trans-
formed from Escherichia coli with separate plasmid vectors
harboring the cDNA for GAPDH (pHcGAP, ATCC no. 57090)
and prepro-ET-1 (ET1c, ATCC no. 65698). Recombinant plas-
mids were purified from 5 ml each of E. coli growth using the
FlexyPrep kit (Pharmacia). After digestion we separated the
cDNA fragments from the plasmid by electrophoresis on a 1%
agarose gel and then purified by cutting the gel slice of the
corresponding molecular insert size (1.2 kb for both ET-1 and
GAPDH) using the BandPrep Kit Sephaglas (Pharmacia).
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Streptavidin-biotinylated horseradish peroxidase complex in
buffered sodium chloride was used as the detection reagent
(28). Specimens were stained with 3-amino-9-ethyl carbazole
(Sigma) for 10 min at 37°C and counterstained with Mayer’s
hematoxylin. To ensure the specificity of the in situ hybridiza-
tion signals, negative controls were performed by testing the
sections with hybridization mixture 1) without the probe and
2) after incubation with RNAase A (1 Kunitz unit/l) for 1 h at
37°C. Positive controls were obtained for each sample using a
cDNA probe for the constitutively expressed GAPDH to
ensure that mRNA in kidney specimens was intact. In situ
hybridization staining was performed at the same time for all
specimens and at least twice on serial sections in each
specimen. The presence of mRNA signals was assessed by
light microscopy.
Statistical Analysis
Data are presented as means 6 SD unless otherwise
indicated. Comparisons of a single observation between groups
were made with ANOVA and Student’s t-test. Multiple com-
parisons among diet groups were made with Tukey’s test.
Repeated observations over the experimental days were
analyzed with ANOVA for repeated measures, with a split-
plot design for differences between days (multivariate analy-
sis of variance). A value of P , 0.05 was considered signifi-
cant. All statistical analyses were performed with BMDP
statistical software (BMDP Statistical Software, Los Angeles,
CA).
RESULTS
Effects of Different Sodium Intakes
The three sodium regimens deeply affected urinary
ET-1 excretion, which increased during the low-sodium
diet (P , 0.05) and decreased during high sodium
intake (P , 0.05) (Fig. 1). ET-1 plasma concentration
was not affected by the low-sodium diet, whereas it
increased significantly after high sodium intake (P ,
0.05) (Fig. 1).
The values of the different analytical parameters
obtained at the end of the 7-day normal-sodium diet are
reported in Table 1.
Urinary ET-1 excretion at the end of the high-sodium
diet period had significantly decreased (228%, P ,
0.05), whereas ET-1 plasma concentration had on aver-
age increased by 103% (P , 0.05) (Table 1). The
decrease in urinary ET-1 excretion became significant
from day 2 (222 %, P , 0.05) and reached a nadir at
day 3 (234%, P , 0.05), and then values plateaued
(Fig. 1, Table 1). PRA decreased from 1.50 6 0.21 to
0.28 6 0.10 ng ANG I·ml21 ·h21 (P , 0.05). GFR did not
change, whereas urinary flow rate and CNa increased
and CH2O decreased (Table 1).
The low-sodium diet was associated with an in-
creased daily ET-1 urinary excretion (from 2.58 6 0.62
to 4.28 6 1.34 pg/min, 166%, P , 0.05). Plasma ET-1
concentration did not change significantly (Fig. 1, Table
1). PRA increased after 2 days of diet (P , 0.05), and it
was 4.26 6 0.37 ng ANG I·ml21 ·h21 (P , 0.05) at the
end of the low-sodium diet. During the low-sodium diet
period, GFR did not significantly change, whereas the
urinary flow rate decreased from 54 6 16 to 46 6 15
ml/h at the end of the diet period (P , 0.05). Similarly,
there was a marked reduction in sodium excretion
(from 117 6 5 to 21 6 3 meq/24 h) and CNa (from 0.57 6
0.02 to 0.10 6 0.01 ml/min, P , 0.05).
At the end of the low-sodium diet, CLi was reduced by
51% (P , 0.05). At the same time, the fraction of sodium
delivered to the distal tubule that is finally excreted,
expressed by the ratio CNa/CLi, decreased by 62% (P ,
0.05) (Table 1). CH2O significantly increased on the
second day (from 20.88 6 0.30 to 20.38 6 0.40 ml/min,
P , 0.05) and rose further up to the seventh day
(20.17 6 0.13 ml/min, P , 0.05) (Table 1).
Urinary ET-1 excretion changes from a normal- to a
low-sodium diet were negatively related to contempo-
rary changes in sodium excretion (r 5 0.97, P , 0.05)
and were positively correlated to CH2O (r 5 0.97, P ,
0.05) (Fig. 2).
In situ hybridization. In situ hybridization studies
performed in kidneys from patients on a normal-
sodium diet showed that the prepro-ET-1 mRNA signal
was present in the smooth muscle cells and endothelial
cells of arcuate and interlobular arteries, whereas
almost no signal was observed within the glomeruli
(Fig. 3). The hybridization signal was observed in the
peritubular capillary network in the cortical region
(Fig. 3), in vasa recta, and in the loose connective tissue
of the inner medulla. In the cortical region the epithe-
lial cells did not show the hybridization signal in either
the proximal or the distal tubule (Fig. 3). A weak,
spotted hybridization signal was observed in the epithe-
lial cells of the medullary collecting tubule (Fig. 3).
In kidneys from patients on the low-sodium diet the
expression of prepro-ET-1 mRNA increased at both the
vascular capillaries and epithelial cells of the collecting
tubule. The hybridization signal was present in the
smooth muscle cells of large vessels located in the renal
columns and in the arcuate and interlobular arteries,
as well as in the radial arteries. In comparison to the
normal-sodium diet, prepro-ET-1 mRNA signal in-
creased in capillary vessels originating from the effer-
ent arteriola and circumventing the proximal and
distal tubules (Fig. 4). No signal was present in the
epithelial cells of the proximal or distal tubules (Fig. 4).
The hybridization signal of mRNA expression had
Fig. 1. Urinary endothelin (ET)-1 excretion (A) and plasma ET-1
concentration (B) in healthy subjects at baseline (day 22 to day 0)
and during three 7-day sodium diet regimens (day 1 to day 7),
indicated by bars. r, Low-sodium diet, 20 meq/day; s, normal-
sodium diet, 108 meq/day; k, high-sodium diet, 300 meq/day. *P ,
0.05 vs. baseline (day 0).
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markedly increased at the epithelial cells of the collect-
ing tubules and ducts (Fig. 4) in comparison to the
normal-sodium diet (Fig. 3).
In conclusion, on a low-sodium diet prepro-ET-1
mRNA expression increased not only in the capillary
network but also in the epithelial cells of the collecting
tubule.
Effects of ACE Inhibition
Ramipril administration started on the eighth day of
the low-sodium diet caused a further increase in PRA
values in the first 24 h (from 4.26 6 0.37 to 12.45 6 0.98
ng ANG I·ml21 ·h21, P , 0.05), without any further
significant variation during the following 6 days. Mean
arterial blood pressure had mildly decreased 3 h after
ramipril administration (from 85 6 6 to 81 6 7 mmHg,
P , 0.05) but returned to baseline levels at the 6-h
measurement (data not shown). ACE inhibition did not
affect ET-1 plasma concentration, although it caused a
sharp and brief decrease in ET-1 urinary excretion in
the first 24 h (from 4.28 6 1.34 to 1.86 6 0.56 pg/min,
256%, P , 0.05); this, however, partially recovered in
the following days (Table 1, Fig. 5A). At the end of the
7-day ramipril treatment ET-1 urinary excretion was
lower than pretreatment (220%, P , 0.05) but signifi-
cantly higher than baseline (131%, P , 0.05) (Table 1).
Sodium excretion showed consensual modifications
to those of ET-1 excretion (Fig. 5B). On the first day of
ramipril administration there was a marked and tran-
sient increase in CNa (from 0.10 6 0.01 to 0.23 6 0.04
ml/min, P , 0.05), which, however, showed a tendency
to return to the pretreatment values (0.13 6 0.02
ml/min, P , 0.05 vs. both pretreatment values and vs.
the first day of ramipril administration). The cumula-
tive sodium balance of the last 3 days of ramipril
treatment, when sodium and ET-1 excretion remained
steady, was 216 6 12 meq in comparison to 22 6 5 meq
(P , 0.05), observed during the low-sodium diet before
ramipril treatment (Fig. 5C).
CLi and CNa/CLi increased during the first 24 h of
ramipril administration (Table 1), whereas CH2O de-
creased. After the first day of ACE inhibition all these
functional indexes returned to the pretreatment val-
ues, whereas CH2O remained significantly reduced in
comparison to pretreatment values (Table 1; Fig. 5D).
Thus the partial recovery of ET-1 excretion despite ACE
inhibition was associated with consensual changes in
CH2O (from 20.52 6 0.11 to 20.29 6 0.16 ml/min, P ,
0.05; Fig. 5D).
When ACE inhibition was started before the low-
sodium diet no significant differences in ET-1 excretion,
urinary volume, sodium excretion, or CH2O were found
in comparison to ACE inhibition started during the
low-sodium diet (data not shown). The very good corre-
lations found between ET-1 excretion and both sodium
Fig. 2. Relationships of urinary ET-1 with sodium excretion (A) and
free water clearance (CH2O; B) during low-sodium diet without (s)
and with (r) angiotensin-converting enzyme (ACE) inhibition. Val-
ues are expressed per unit of glomerular filtration rate (GFR).
Table 1. Effects of 3 different 7-day sodium diet regimens: angiotensin-converting enzyme inhibition
during low-sodium diet
300 meq Na 108 meq Na
20 meq Na 20 meq Na1Ramipril
Day 1 Day 7
% vs.
baseline Day 8 Day 14
% vs.
baseline
Plasma ET-1,
pg/ml 0.7560.09* 0.3760.03 0.4160.08 0.4460.08 119 0.4060.09 0.3560.08 25
Urinary ET-1,
pg/ml 1.7560.45 4.1761.82 3.9361.52 5.5262.42*† 132 2.3160.89*†‡ 4.8862.30‡§ 117
Urinary ET-1,
pg/min 1.8560.44* 2.5860.62 3.4261.01 4.2861.34* 166 1.8660.56*†‡ 3.3861.22*‡§ 131
Urinary flow
rate, ml/h 65613* 54616 51616 46615* 215 52625 51621 25
CCr, ml/min 118621 112620 115618 114633 12 100625 115645 13
CNa, ml/min 1.6560.37 0.5760.02 0.4560.04* 0.1060.01*† 282 0.2360.04*†‡ 0.1360.02*†‡§ 277
CLi, ml/min 29.366.3 25.165.9 24.465.6 12.363.9*† 251 17.263.4*†‡ 14.563.0*†§ 242
CNa/CLi, % 5.861.6 2.460.5 1.960.4* 0.960.3*† 262 1.460.3*†‡ 0.960.3*†§ 262
CH2O, ml/min 22.8760.56* 20.8860.30 20.7860.16 20.1760.13*† 181 20.5260.11*†‡ 20.2960.16*†‡§ 167
CLi 2CNa, ml/min 27.766.2* 24.565.9 23.965.6 12.263.9*† 250 17.063.4*†‡ 14.463.0*†§ 241
Values are means 6 SD. ET-1, endothelin-1; CCr, creatinine clearance; CNa, sodium clearance; CLi, lithium clearance; CH2O, free water
clearance. *P , 0.05 vs. baseline; †P , 0.05 vs. day 1; ‡P , 0.05 vs. day 7; §P , 0.05 vs. day 8.
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excretion and CH2O during the low-sodium diet were
also maintained when the low-sodium diet was started
under ACE inhibition (r 5 0.99, P , 0.05 and r 5 0.98,
P , 0.05, respectively), although they had slightly
shifted to the left (Fig. 2).
DISCUSSION
The present findings indicate that a low sodium
intake is associated with an increase in prepro-ET-1
mRNA expression in endothelial cells of the peritubular
capillary network and, especially, in epithelial cells of
the medullary collecting tubules. These changes of
mRNA expression for prepro-ET-1 were associated with
increased urinary ET-1 excretion. Conversely, the high-
sodium diet was associated with a decrease in urinary
ET-1 excretion.
Our results demonstrate for the first time that renal
ET-1 synthesis in humans is affected by changes in
sodium intake. The modifications in renal prepro-ET-1
mRNA expression were associated with consensual
variations in urinary ET-1 excretion, thus indicating
that urinary ET-1 excretion is the main expression of
renal ET-1 formation. Previous studies showed that
infusion of 30 ml/kg of a 5% glucose solution over 1 h
caused a marked increase in plasma ET-1 concentra-
tion associated with an almost complete disappearance
of urinary ET-1 (21). In the present study the increase
in urinary ET-1 excretion without any changes in
plasma ET-1 during low sodium intake, and, con-
versely, the increased plasma ET-1 concentration with
a contemporary decrease in ET-1 excretion after a
high-sodium diet, suggest that plasma ET-1 and renal
ET-1 are two independent compartments.
The expression of mRNA for prepro-ET-1 during the
low-sodium diet increased in the endothelial cells of the
peritubular capillary network and in the epithelial cells
of the medullary collecting tubules. Although the contri-
bution of this ET-1 arising from endothelial cells to the
total amount of urinary ET-1 cannot be ruled out, it is
probably negligible, because studies performed in rats
showed that only trace amounts of injected 125I-labeled
ET-1 passed in the urine (from 0.27 to 0.30% of the total
infused 125I-labeled ET-1) (1); as a consequence, the
urinary ET-1 almost entirely derives from the renal
tubule.
The increased renal ET-1 formation was associated
Fig. 3. In situ hybridization in kidney specimens from patients on normal-sodium diet. A: no signal for
preproendothelin (prepro-ET-1) mRNA was observed within glomeruli and in epithelial cells; positive prepro-ET-1
mRNA hybridization signal in peritubular capillary network (3200). B: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression in epithelial cells of inner medulla (31,000). C and D: weak, spotted prepro-ET-1
mRNA hybridization signal was observed in epithelial cells of medullary collecting tubule in longitudinal (C) and
transverse (D) sections (31,000).
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with an enhancement in sodium retention. The in-
creased prepro-ET-1 mRNA expression in endothelial
cells of the postglomerular vascular capillary network
circumventing the proximal and distal tubules prob-
ably contributes to the mild decrease in renal blood flow
that occurs during low sodium intake (9). The decrease
in renal blood flow mainly occurs in the renal medulla,
where vasoconstrictor ETA receptors are highly ex-
Fig. 4. In situ hybridization for prepro-ET-1 mRNA in kidney specimens from patients on low-sodium diet. A:
increased hybridization signal in peritubular capillary network; no signal is detectable in epithelial cells of the
proximal as well as of the distal tubule (3200). B: in situ hybridization of RNAase-treated specimen (31,000). C and
D: hybridization signal of prepro-ET-1 mRNA expression in epithelial cells of collecting tubules in longitudinal (C)
and transverse (D) sections (31,000).
Fig. 5. Effects of ACE inhibition (day 8 to day 14) in
patients on low-sodium diet (day 1 to day 14) on rate of
ET-1 urinary excretion (A), urinary sodium excretion
(B), and cumulative sodium balance of last 3 days of
each period (C), and CH2O (D). *P , 0.05 vs. baseline
(day 0).
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pressed on interstitial cells and pericytes of the vasa
recta (6). As a consequence of the decreased blood flow,
the medullary osmolarity increases; this in turn pro-
duces an augmented sodium reabsorption (9). This
sequence of events is suggested by the decreased frac-
tion of sodium delivered to the distal tubule that is
finally excreted (CNa/CLi). This distal sodium reabsorp-
tion was largely independent of ANG II activity, be-
cause ramipril administration only mildly reduced
distal sodium reabsorption (Table 1). Thus these find-
ings suggest a sodium-retentive activity of ET-1 in vivo.
Several experimental findings obtained in vitro seem to
speak against a sodium-retentive activity of ET-1. In a
suspension of isolated IMCD cells, ET-1 has been
demonstrated to inhibit Na1-K1-ATPase activity (34)
and to inhibit Na1 channels in the luminal membrane
by a Ca1-dependent process in the cortical collecting
duct cells (14), thus resulting in a decrease of sodium
entry from the lumen of epithelial cells. However, the
effects of ET-1 in vivo appear to be more complex.
Clavell et al. (6), using selective ETA and ETB antago-
nists, elegantly showed in dogs that the natriuretic
effect of ET-1 at the level of epithelial cells becomes
evident only when ETA vasoconstrictor receptors are
selectively blocked. When ET-1 was infused in humans
at low doses (1 ng·kg21 ·min21), it caused sodium
retention accompanied by a fall in the fractional excre-
tion of lithium (25). Thus, in vivo, the sodium-retentive
activity of ET-1 seems to prevail over the natriuretic
effect found in in vitro studies. The increased sodium
retention resulting from the increased medullary osmo-
lality found in the present investigation may be consid-
ered as an indirect effect of ET-1, but the net result is a
reduced sodium excretion.
An increased CH2O was the other important func-
tional modification associated with the increase in ET-1
urinary excretion. In addition to the peritubular capil-
laries, a marked increase in mRNA expression for ET-1
was also observed at the epithelial cells of inner
medullary collecting tubules and ducts during low
sodium intake. AVP secretion is the only condition
affecting CH2O, and thus a decrease in this secretion
might be responsible for the increase in CH2O observed
in subjects during the low-sodium diet. We did not measure
AVP plasma concentration, but it does not increase in
low sodium intake (4). Several studies have shown that
ET-1 negatively modulates the effects of AVP on the
distal tubule by inhibiting both AVP-stimulated cAMP
accumulation (12) and water permeability in the rat
terminal IMCD (20, 23, 29). Therefore, the increased
CH2O seems to be attributable to the increased ET-1
formation by the epithelial cells of the collecting tu-
bules and ducts.
The factors responsible for the increased ET-1 renal
formation remain to be clarified. Several studies have
shown that ANG II increases mRNA expression for
prepro-ET-1 in isolated cells (27). Therefore, the in-
creased mRNA expression for prepro-ET-1 in the endo-
thelial cells of the peritubular capillary network found
during low sodium intake might be caused by the
increased ANG II formation. In the present investiga-
tion, changes in ET-1 urinary excretion paralleled
renin-angiotensin system activity. The further PRA
increase after ramipril administration in patients on a
low-sodium diet is an index of the inhibition of ACE and
then of a reduced ANG II formation. However, ET-1
excretion was only partially reduced by ACE inhibition,
thus indicating that renal ET-1-forming activity was
largely independent of the renin-angiotensin system.
Moreover, the increased kinin activity that occurs
during ACE inhibition (2) might directly inhibit ET-1
renal production, because previous studies showed that
bradykinin inhibited ET-1 production from cultured
endothelial cells (18).
An increase in renal medulla osmolality was found to
stimulate mRNA expression for prepro-ET-1 in rat and
rabbit epithelial tubular cells (16, 33). Moreover, re-
duced renal perfusion in rats and rabbits considerably
enhanced ET-1 synthesis by the epithelial cells of the
medullary tubules (7). During low sodium intake, blood
flow decreases and medullary osmolality increases (9).
Thus the increased medullary osmolality rather than
PRA appears to be the main factor causing the in-
creased mRNA expression for prepro-ET-1.
Plasma ET-1 levels increased during high sodium
intake in contrast to the decrease in urinary ET-1
excretion. The augmented plasma ET-1 levels are prob-
ably caused by the volume expansion that occurs in this
condition (26), because experimental acute volume
expansion (21) or spontaneous chronic volume expan-
sion as observed in congestive heart failure (27) were
both found to be associated with increased plasma ET-1
levels.
In conclusion, the present results indicate that renal
ET-1 is influenced by sodium intake. More particularly,
a low-sodium diet is associated with increased mRNA
expression for prepro-ET-1 both in the endothelial cells
of the peritubular capillaries and in the epithelial cells
of the medullary collecting tubules. The increase in
ET-1 synthesis is associated with an increase in both
sodium retention and CH2O. The enhanced mRNA ex-
pression for prepro-ET-1 in the endothelial cells of the
peritubular capillaries is indirectly responsible for the
increased sodium reabsorption, which is mediated by
the enhanced medullary osmolality, whereas the in-
creased synthesis of ET-1 by the epithelial cells of the
medullary collecting ducts may explain the increase in
CH2O observed during a low-sodium diet.
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